Active and passive immunotherapy for neurodegenerative disorders

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Immunotherapy for neurodegenerative disorders, including Alzheimer disease (AD), has shown early promise in preclinical models.
• Initial active amyloid-beta (Abeta) vaccination trials in humans were discontinued due to meningoencephalitis.
• Despite setbacks, advancements in active and passive immunotherapeutic strategies are progressing, with many in human trials for AD.

Purpose of the Study:

• To review the progress and challenges of immunotherapeutic strategies for neurodegenerative disorders, particularly AD.
• To explore the evolving landscape of active and passive immunotherapies.
• To highlight the incomplete understanding of the underlying mechanisms of therapeutic effects.

Main Methods:

• Review of preclinical and clinical studies on immunotherapy for neurodegenerative diseases.
• Analysis of safety and efficacy data from early human trials.
• Discussion of proposed mechanisms of action for immunotherapies.

Main Results:

• Early human trials of active Abeta vaccination faced significant safety concerns (meningoencephalitis).
• Encouraging preliminary data exist for alternative immunotherapeutic approaches.
• Several novel active and passive immunotherapies are currently in human trials for AD.

Conclusions:

• Immunotherapy remains a promising avenue for treating neurodegenerative disorders, with ongoing development of safer strategies.
• A comprehensive understanding of the diverse mechanisms driving therapeutic effects is still needed.
• Continued research is crucial for optimizing immunotherapeutic interventions for conditions like AD.